Caremark Rx is attempting to cut pricing on its $225 million "B" term loan by 3/4% after improving the credit profile of the company in the last year. The pharmacy-benefit management (PBM) company is back in the market with lead banker Bank of America. "We refinanced the bank facility last year leaving a "B" loan outstanding. But since then, the company has improved the credit, been upgraded to BB+ by Standard & Poor's, and so is looking to improve interest payments," explained Howard McClure, executive v.p. and cfo of Caremark.
April 04, 2002